Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Endpoints
Mon, 02/19/18 - 11:46 am
Tags:
Eli Lilly, rheumatoid arthritis, Hanmi Pharmaceutical, clinical trials
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
Xconomy
Tue, 02/13/18 - 11:02 pm
Tags:
Eli Lilly, Taltz
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Endpoints
Tue, 02/13/18 - 09:45 am
Tags:
Eli Lilly, Taltz, Novartis, ankylosing spondylitis, Cosentyx
Lilly, Livongo team up for real-world diabetes research, aiming for better results in an outcomes-oriented market
Fierce Pharma
Mon, 02/12/18 - 04:31 pm
Tags:
Eli Lilly, Livongo, diabetes, R&D
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Mon, 02/12/18 - 11:00 am
Tags:
Novo Nordisk, semaglutide, Eli Lilly, Ozempic, Trulicity
Biopharma in charts: Key takeaways from Q4 earnings
Biopharma Dive
Mon, 02/5/18 - 12:35 pm
Tags:
earnings, Merck, JNJ, AbbVie, Roche, Celgene, Eli Lilly
Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls
TheStreet.com
Sat, 02/3/18 - 09:07 am
Tags:
pharma execs, M&A, earnings, drug pricing, Pfizer, Ian Read, Merck, Ken Frazier, Enrique Conterno, Eli Lilly
The Viagra effect: Sales of Lilly's ED drug Cialis slide after little blue pill goes generic
Fierce Pharma
Wed, 01/31/18 - 03:16 pm
Tags:
Eli Lilly, Pfizer, erectile dysfunction, Viagra, Cialis, generics
Racing to replace opioids, biopharma is betting on pain drugs with a checkered past
Stat
Wed, 01/31/18 - 11:00 am
Tags:
opioids, painkillers, NGF inhibitors, Regeneron, Pfizer, Eli Lilly, NGF blockers
Eli Lilly Cruises Through Q4 Earnings
Yahoo/24-7 Wall St
Wed, 01/31/18 - 09:21 am
Tags:
Eli Lilly, earnings
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s
Endpoints
Thu, 01/25/18 - 09:31 am
Tags:
Eli Lilly, clinical trials, Alzheimer's disease, solanezumab
Senate panel approves HHS nominee Azar
Mass Device
Thu, 01/18/18 - 09:58 am
Tags:
HHS, Alex Azar, Senate, Eli Lilly
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Fierce Pharma
Thu, 01/11/18 - 11:56 pm
Tags:
Eli Lilly, M&A, immunology
Lilly CEO: With pharma friends in high places, it's 'time for action' to ease drug costs
Fierce Pharma
Wed, 01/10/18 - 06:58 pm
Tags:
Eli Lilly, Pharma CEOs, David Ricks, drug pricing, JPMHC 2018
[video]Eli Lilly CEO: It's a great time for science in pharma sector
Yahoo/CNBC
Mon, 01/8/18 - 11:28 am
Tags:
Eli Lilly, Pharma CEOs, David Ricks, JPMHC 2018
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
Fri, 01/5/18 - 10:28 am
Tags:
China, Opdivo, Repatha, Lynparza, drug approvals, Bristol-Myers Squibb, Amgen, AstraZeneca, Eli Lilly, Gilead Sciences
Pfizer takes on Novartis, Lilly with Xeljanz psoriatic arthritis approval
Fierce Pharma
Fri, 12/15/17 - 11:27 pm
Tags:
Pfizer, Novartis, Eli Lilly, Xeljanz, psoriatic arthritis
Lilly's 2018 forecast beats on strength of new drugs
Yahoo/Reuters
Wed, 12/13/17 - 09:41 am
Tags:
Eli Lilly, Trulicity, Taltz
Lilly Nixes Expansion of Stomach Cancer Drug After Mixed Study Results
Xconomy
Mon, 12/11/17 - 11:18 pm
Tags:
Eli Lilly, stomach cancer, Cyramza
Juno inks deals with Eli Lilly as it looks to leapfrog leaders on BCMA
Endpoints
Thu, 12/7/17 - 08:56 am
Tags:
Juno Therapeutics, Eli Lilly, LY3039478, Multiple Myeloma

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.